CliffBio
biologic

Udenyca

pegfilgrastim-cbqv

Loss of exclusivity—loss of exclusivity
CompanyAccord Biopharma →See this company's full patent-cliff portfolio

Drug detail

Brand nameUdenyca
Active ingredientpegfilgrastim-cbqv
Strength6MG/0.6ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalNovember 2018
Marketing statusRx

More from Accord Biopharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Udenyca patent cliff — loss of exclusivity — | CliffBio